You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Focal Segmental Glomerulosclerosis

Showing 1 - 25 of 1,573
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Genetic Markers for Focal Segmental Glomerulosclerosis

Completed
  • Focal Segmental Glomerulosclerosis
  • HIV-Associated Focal Segmental Glomerulosclerosis
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 26, 2023

    Focal Segmental Glomerulosclerosis and Minimal Change Disease

    Not yet recruiting
    • Focal Segmental Glomerulosclerosis
    • +3 more
    • Biospecimen collection
    • Data collection
    • Ann Arbor, Michigan
      University of Michigan
    Dec 6, 2022

    Focal Segmental Glomerulosclerosis Trial (Metformin + Standard of Care, Placebo + Standard of Care)

    Not yet recruiting
    • Focal Segmental Glomerulosclerosis
    • Metformin + Standard of Care
    • Placebo + Standard of Care
    • (no location specified)
    Oct 13, 2023

    LDL-Apheresis for FSGS CardioRenal Outcomes

    Enrolling by invitation
    • Focal Segmental Glomerulosclerosis
    • No intervention
    • Cincinnati, Ohio
    • +1 more
    Jan 25, 2023

    Focal Segmental Glomerulosclerosis (FSGS) Trial (VX-147)

    Not yet recruiting
    • Focal Segmental Glomerulosclerosis (FSGS)
    • (no location specified)
    Jul 13, 2023

    Minimal Change Disease, Focal Segmental Glomerulosclerosis Trial in United States (VB119)

    Recruiting
    • Minimal Change Disease
    • Focal Segmental Glomerulosclerosis
    • Los Angeles, California
    • +7 more
    Jul 19, 2022

    Focal Segmental Glomerulosclerosis (FSGS) Trial (IXP)

    Not yet recruiting
    • Focal Segmental Glomerulosclerosis (FSGS)
    • (no location specified)
    May 9, 2023

    Focal Segmental Glomerulosclerosis Trial in Australia (Propagermanium, Placebo)

    Completed
    • Focal Segmental Glomerulosclerosis
    • Gosford, New South Wales, Australia
    • +10 more
    Jul 28, 2022

    IgA Nephropathy, Focal Segmental Glomerulosclerosis Trial in Nanjing (HS-10390 tablet, Placebo tablet)

    Recruiting
    • IgA Nephropathy
    • Focal Segmental Glomerulosclerosis
    • HS-10390 tablet
    • Placebo tablet
    • Nanjing, Jiangsu, China
      Zhongda Hospital, Affiliated to Southeast University
    Jul 12, 2023

    FSGS, MCD, Focal Segmental Glomerulosclerosis Trial in United States (adalimumab)

    Recruiting
    • FSGS
    • +3 more
    • Ann Arbor, Michigan
    • +3 more
    Jan 31, 2022

    Humanistic Burden of Focal Segmental Glomerulosclerosis and IgAN

    Recruiting
    • Focal Segmental Glomerulosclerosis
    • Immunoglobulin A Nephropathy
      • Belmar, New Jersey
      • +2 more
      Apr 12, 2022

      Alport Syndrome, Focal Segmental Glomerulosclerosis Trial in United States (R3R01)

      Recruiting
      • Alport Syndrome
      • Focal Segmental Glomerulosclerosis
      • Los Angeles, California
      • +10 more
      Aug 15, 2022

      Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Idiopathic Nephrotic Syndrome Trial in Cologne (Biosampling)

      Recruiting
      • Glomerulosclerosis, Focal Segmental
      • +2 more
      • Biosampling
      • Cologne, NRW, Germany
        University Hospital of Cologne
      Nov 12, 2021

      Focal Segmental Glomerulosclerosis Trial in United States (LIPOSORBER® LA-15 System)

      Recruiting
      • Focal Segmental Glomerulosclerosis
      • LIPOSORBER® LA-15 System
      • Loma Linda, California
      • +11 more
      Mar 28, 2022

      Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis Trial in New Hyde Park, Philadelphia

      Recruiting
      • Nephrotic Syndrome in Children
      • +2 more
      • Transcutaneous auricular vagus nerve stimulation
      • Sham device
      • New Hyde Park, New York
      • +1 more
      Dec 23, 2022

      Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis Trial in New Hyde Park, Philadelphia

      Recruiting
      • Nephrotic Syndrome in Children
      • +2 more
      • trascutaneous auricular vagus nerve stimulation
      • Sham device
      • New Hyde Park, New York
      • +1 more
      Dec 19, 2022

      Kidney Disease, Chronic Trial in Australia, Spain, United States (BI 764198, Placebo)

      Recruiting
      • Kidney Disease, Chronic
      • BI 764198
      • Placebo
      • S. Gate, California
      • +15 more
      Aug 8, 2022

      Focal Segmental Glomerulosclerosis Trial in United States (Rituximab, Plasmapheresis)

      Recruiting
      • Focal Segmental Glomerulosclerosis
      • Tuscaloosa, Alabama
      • +13 more
      Nov 16, 2021

      Primary Focal Segmental Glomerulosclerosis Trial in Rochester (Obinutuzumab)

      Recruiting
      • Primary Focal Segmental Glomerulosclerosis
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Dec 13, 2021

      Glomerulosclerosis, Focal Segmental Trial in Worldwide (VX-147)

      Completed
      • Glomerulosclerosis, Focal Segmental
      • Birmingham, Alabama
      • +43 more
      Nov 10, 2022

      Focal Segmental Glomerulosclerosis Trial in Dominican Republic, United States (Voclosporin)

      Terminated
      Has Results
      • Focal Segmental Glomerulosclerosis
      • Denver, Colorado
      • +22 more
      Aug 20, 2021

      NEPTUNE Match Study

      Enrolling by invitation
      • Nephrotic Syndrome in Children
      • +7 more
      • Communication
      • Atlanta, Georgia
      • +15 more
      Jan 30, 2023

      Rituximab for Refractory or Relapsed Focal Segmental

      Completed
      • Focal Segmental Glomerulosclerosis
      • Minimal Change Disease
        • Istanbul, Turkey
          Istanbul University
        Nov 28, 2020

        Adult and Child Patients and Parents of Swelling Due to

        Recruiting
        • Fluid Overload
        • +12 more
        • Interview
        • Ann Arbor, Michigan
          University of Michigan
        Aug 16, 2022

        Focal Segmental Glomerulosclerosis (FSGS) Trial in Worldwide (PF-06730512)

        Active, not recruiting
        • Focal Segmental Glomerulosclerosis (FSGS)
        • Birmingham, Alabama
        • +59 more
        Aug 17, 2022